MPM nets big return on Idenix exit
The US life sciences investor has sold the hepatitis and HIV treatment company to Novartis in a deal that values the business at up to $612m.
The US life sciences investor has sold the hepatitis and HIV treatment company to Novartis in a deal that values the business at up to $612m.
Copyright PEI Media
Not for publication, email or dissemination